Recherchez et trouvez le CMO / CDMO dont vous avez besoin
Discover highly skilled partners for your drug development and manufacturing project.
Cenexi Hérouville Saint Clair
Cenexi
Le site d'Hérouville-Saint-Clair, situé près de Caen, en Normandie, est spécialisé dans la fabrication et le remplissage de liquides stériles injectables et non
SUBSTANCES CONTRÔLÉES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse
MARCHÉS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), ANVISA (Brazil), Russian Health Authorities, MHRA (UK), MFDS (South Korea), TGA (Australia)
RÉGION: Europe
COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), NMPA (BPF de Chine), EMA (BPF DE L'UE), MHRA (BPF AU ROYAUME-UNI), MFDS/KFDA (République de Corée GMP)
USAGE: Humain
SERVICES: Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (N) Nervous system, (A) Digestive tract and metabolism
OEB (bandes d´exposition professionnelle): 4 / HPAPI (PDE = 10 - 100 µg/jour), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day)
TAILLE DU LOT: Petit, Moyen
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
Cenexi Laboratoires Thissen
Cenexi
Cette usine de 8.000 m2, répartie sur un terrain de près de sept hectares, est située à 20 km au sud de Bruxelles et compte 340 salariés*.
OEB (bandes d´exposition professionnelle): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day)
BSL (niveau de sécurité biologique): 3, 4, 1, 2
SUBSTANCES CONTRÔLÉES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse
MARCHÉS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), TGA (Australia)
RÉGION: Europe
COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), TGA (Australia GMP), NMPA (BPF de Chine), EMA (BPF DE L'UE), Santé Canada (Canada GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), MFDS/KFDA (République de Corée GMP)
TAILLE DU LOT: Grandes dimensions, Petit, Moyen
USAGE: Humain, Vétérinaire
SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (L) Antineoplastic and immunomodulating agents, (G) Genito urinary system and sex hormones
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
OEB (bandes d´exposition professionnelle): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour)
BSL (niveau de sécurité biologique): 3, 4
SUBSTANCES CONTRÔLÉES: High potential for abuse & medical use
COMPLIANCE: ICH, ISO, ANVISA (Brazil B-GMP), TITCK (Turkish Health Authorities), SFDA (Saudi Food & Drug Authority), NMPA (BPF de Chine), EMA (BPF DE L'UE)
MARCHÉS: EMA (EU), NMPA (China), ANVISA (Brazil), MHRA (UK), SFDA (Saudi Arabia), Turkish Health Authorities
SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
RÉGION: Europe
TAILLE DU LOT: Grandes dimensions, Petit, Moyen
USAGE: Humain
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (L) Antineoplastic and immunomodulating agents
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
CHEMICAL-SYNTHETIC manufacturing site
MAI network supplier
Solutions pour les programmes de distribution non virale
Location available after registration
FDF / DRUG PRODUCTS manufacturing site
MAI network supplier
CDMO pharmaceutique de bout en bout
Location available after registration
SERVICES manufacturing site
MAI network supplier
Flacons liquides et lyophilisés - Deux salles blanches conformes à l'Annexe I BSL-2.
Location available after registration
These facilities match your main criteria but not all optional filters.
Laboratorios Grifols | Murcia Plant
Grifols International
Solutions de fabrication stériles (petites molécules) en sacs souples.
MARCHÉS: ANMAT (Argentina), ANVISA (Brazil), FDA (USA), EMA (EU), MFDS (South Korea), TGA (Australia)
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
COMPLIANCE: ISP (Chile BPM), ANMAT (Argentine nouveau GMP), EMA (BPF DE L'UE), ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), TGA (Australia GMP), FDA (cGMP), ECOVADIS, ISO, INVIMA, Santé Canada (Canada GMP), MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain, Vétérinaire
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Packaging, Quality Assurance services
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (M) Musculoskeletal system, (J) Antiinfectives for systemic use, (C) Cardiovascular system, (A) Digestive tract and metabolism, (N) Nervous system
Adragos Pharma | Halden
Adragos Pharma
Nous sommes spécialisés dans la fabrication de poches IV, d'ampoules et de flacons en plastique utilisant la technologie Blow-Fill-Seal (BFS) et d'autres formes
MARCHÉS: Turkish Health Authorities, EDE (UAE), ANVISA (Brazil), PMDA (Japan), FDA (USA), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), MHRA (UK)
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
COMPLIANCE: EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), UAE Ministry of Health & Prevention, ANVISA (Brazil B-GMP), Organisation mondiale de la santé (BPF / HACCP), MHRA (BPF AU ROYAUME-UNI), TGA (Australia GMP), FDA (cGMP), NSF, NMPA (BPF de Chine), ISO, TITCK (Turkish Health Authorities), MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (A) Digestive tract and metabolism, (D) Dermatologicals, (V06) Nutrients
Adragos Pharma | Kawagoe
Adragos Pharma
Notre usine offre la meilleure fabrication de comprimés et d’ampoules.
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS, SERVICES
MARCHÉS: EDE (UAE), PMDA (Japan), FDA (USA), CDSCO (India), EMA (EU), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), MHRA (UK)
COMPLIANCE: EMA (BPF DE L'UE), PMDA/MHLW (Japan GMP), FDA (cGMP)
TAILLE DU LOT: Grandes dimensions
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
USAGE: Humain
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services
RÉGION: APAC
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
Adragos Pharma | Livron
Adragos Pharma
Fabrication de liquides stériles et de suppositoires. Nous traitons plus de 100 molécules, la gestion des stupéfiants et les services d'analyse et de stabilité.
TAILLE DU LOT: Petit, Moyen, Grandes dimensions
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
COMPLIANCE: EMA (BPF DE L'UE), MFDS/KFDA (République de Corée GMP)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain
SERVICES: Analytical / QC services, Logistics, Manufacturing services, Regulatory services, Packaging, Quality Assurance services
MARCHÉS: PMDA (Japan), CDSCO (India), EMA (EU), MFDS (South Korea), TGA (Australia), NMPA (China), MHRA (UK)
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
Green Phoenix Labs GmbH
Green Phoenix Labs GmbH
Entreprise de thérapie cellulaire avec une capacité excédentaire de salle blanche.
TAILLE DU LOT: Petit, Moyen
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS, SERVICES, BIOLOGIE
COMPLIANCE: EMA (BPF DE L'UE)
SUBSTANCES CONTRÔLÉES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse
RÉGION: Europe
USAGE: Humain
SERVICES: Logistics, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
BSL (niveau de sécurité biologique): 1
MARCHÉS: EMA (EU)
Seda Pharma Development Services
Seda Pharma Development Services Ltd
Seda Pharmaceutical Development Services est spécialisé dans le développement pharmaceutique intégré et la pharmacologie clinique.
MARCHÉS: DIGEMID (Peru), ANMAT (Argentina), Turkish Health Authorities, EDE (UAE), Rest of World, ANVISA (Brazil), ISP (Chile), PMDA (Japan), FDA (USA), MSPAS (Guatemala), CDSCO (India), Russian Health Authorities, EMA (EU), COFEPRIS (Mexico), MFDS (South Korea), SFDA (Saudi Arabia), TGA (Australia), NMPA (China), Health Canada (Canada), INVIMA (Colombia), MHRA (UK)
TAILLE DU LOT: Petit, Moyen
CATÉGORIE / PRODUIT: FDF / DRUG PRODUCTS
RÉGION: Europe
USAGE: Humain
COMPLIANCE: MHRA (BPF AU ROYAUME-UNI), ECOVADIS
SERVICES: Analytical / QC services, Manufacturing services, Regulatory services, Development services, Packaging, Quality Assurance services
OEB (bandes d´exposition professionnelle): 2 (PDE = 1,000 - 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/jour), 1 / low-hazard (PDE > 10,000 µg/day), 3 (PDE = 100 - 1 000 µg/jour)
DOMAINES THÉRAPEUTIQUES D´EXPERTISE (ATC): (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism, (D) Dermatologicals, (N) Nervous system, (B) Blood and blood forming organs
More facilities on the network
Register to unlock the full catalog with contact details and locations.
+19 more facilities
Create free account